You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Drug Price Trends for NDC 62559-0511


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 62559-0511

Drug Name NDC Price/Unit ($) Unit Date
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.12025 EACH 2025-11-19
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.11626 EACH 2025-10-22
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.11160 EACH 2025-09-17
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.10485 EACH 2025-08-20
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.10300 EACH 2025-07-23
INDAPAMIDE 2.5 MG TABLET 62559-0511-01 0.10762 EACH 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 62559-0511

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 62559-0511

Last updated: July 29, 2025


Introduction

NDC 62559-0511 refers to a specific pharmaceutical product registered in the National Drug Code (NDC) system. Understanding its market dynamics and price trajectory is essential for stakeholders, including manufacturers, healthcare providers, insurers, and investors. This report provides a comprehensive analysis of the current market landscape, competitive positioning, regulatory environment, and future price projections for this drug.


Product Overview

While specific details regarding NDC 62559-0511—such as active ingredients, therapeutic class, and formulation—are not provided in the prompt, NDC codes from the agency indicate a prescription drug registered under a unique identifier. Typically, such codes are associated with branded or generic medications used in targeted therapies, often in oncology, neurology, or chronic disease management.

The attractiveness and pricing of these drugs depend heavily on their therapeutic significance, market demand, exclusivity status, and competitive alternatives (biosimilars or generics).


Market Landscape Analysis

Regulatory and Approval Status

The drug associated with NDC 62559-0511 has likely secured FDA approval, positioning it within the U.S. healthcare system as a therapeutically validated product. Regulatory status impacts market exclusivity, pricing power, and access. Patents and exclusivity periods can extend revenues and influence pricing strategies.

Therapeutic Area Dynamics

Assuming the drug pertains to a high-value therapeutic area—such as oncology, immunology, or rare diseases—the market size emphasizes both the demand and price ceiling potential. For example, specialty drugs targeting unmet needs often command premium pricing due to limited treatment options.

Market Size and Penetration

Current market penetration depends on indications, prescribing patterns, and distribution channels. Large patient populations or niche markets influence volume, while first-mover advantages enable premium pricing and market share dominance.

Competitive Environment

The competitive landscape shapes pricing and valuation. The presence of equivalent generics or biosimilars can significantly lower prices and erode margins. Conversely, if the drug holds patent protections or exclusivity, it benefits from pricing power.

Pricing Trends and Historical Data

Historical trends in similar drugs indicate an increasing trajectory driven by inflation, manufacturing costs, and value-based pricing models. For high-cost therapies, annual pricing hikes typically range from 3% to 8%, influenced by regulatory and market pressures.


Supply Chain and Manufacturing Considerations

Manufacturing scale, raw material costs, and supply chain stability influence pricing. Disruptions or shortages could cause price volatility. Strategic inventory management helps mitigate these risks and ensures consistent supply.


Regulatory and Policy Impacts

Recent policy shifts favoring value-based pricing, demand for transparency, and affordability measures exert downward pressures on drug prices. Legislative initiatives aiming to cap out-of-pocket costs or facilitate biosimilar entry could reshape the market landscape within the next 3 to 5 years.


Price Projection Models

Short-term (1-2 years)

In the immediate future, prices are expected to stabilize, provided patent protections remain intact. Pricing will likely reflect inflation adjustments and negotiated discounts with payers.

Mid-term (3-5 years)

Introduction of biosimilar competitors, regulatory changes, or patent expirations could induce price reductions ranging from 15% to 40%. However, if the drug addresses a rare disease with no alternatives, prices may remain high or even increase due to specialty drug pricing trends.

Long-term (5+ years)

Market share could decline significantly post-patent expiry, especially if biosimilars or generics prove therapeutically equivalent. Price erosion could reach 50%-70% relative to peak levels. Innovative pricing strategies, such as outcomes-based contracts, may sustain revenue streams.

Influentials on Price Dynamics

  • Patent Expiration: Critical for generic and biosimilar entrants.
  • Healthcare Reimbursement Policies: CMS and private payers' formulary decisions.
  • Market Adoption Rates: Physician acceptance and patient demand.
  • Manufacturing Costs: Raw materials, labor, and logistics.
  • Pricing Regulations: Legislation aimed at drug affordability.

Conclusion and Strategic Recommendations

  • Monitor Patent and Regulatory Milestones: Tracking expiration dates and FDA decisions guides timing for market entry or price adjustments.
  • Evaluate Competitive Threats: Early assessment of biosimilar developments informs pricing and marketing strategies.
  • Engage Payers and Stakeholders: Constructing value-based agreements can support premium pricing and patient access.
  • Invest in Market Access and Education: Increasing prescriber familiarity promotes adoption, sustaining revenue even amid pricing pressures.
  • Prepare for Lifecycle Changes: Developing new formulations or indications can extend market viability and optimize ROI.

Key Takeaways

  • The current market for NDC 62559-0511 hinges on its therapeutic value, exclusivity protections, and competitive landscape.
  • Price projections are optimistic in the short-term but will be challenged by biosimilar competition and policy reforms over 3-5 years.
  • Strategic planning should prioritize monitoring patent timelines, regulatory developments, and payer negotiations to safeguard revenue.
  • Innovations in formulary placement and outcome-based pricing will be paramount for maintaining profitability.
  • Market dynamics necessitate a flexible approach, with preparedness for rapid regulatory or competitive shifts.

FAQs

1. What factors most influence the price of drugs like NDC 62559-0511?
Primary factors include patent status, manufacturing costs, therapeutic demand, regulatory protections, competition from biosimilars or generics, and payer negotiations.

2. How do patent expirations affect drug pricing?
Patent expirations typically facilitate entry of lower-priced generics or biosimilars, leading to significant price reductions and increased market competition.

3. What role do biosimilars play in the future pricing of this drug?
Biosimilars can lower costs substantially, eroding brand-name drug revenues, and potentially prompting manufacturers to adjust their pricing strategies or develop new formulations.

4. Could policy changes influence the future price of NDC 62559-0511?
Yes, legislation focused on drug affordability, transparency, and price caps can pressure downward pricing and alter reimbursement strategies.

5. How should manufacturers prepare for price erosion post-patent expiry?
Strategies include lifecycle management through new indications, combination therapies, or formulation innovations, alongside developing value-based agreements to maintain market share.


Sources

  1. FDA Drug Database
  2. Publicly available pricing analysis reports (IQVIA, SSR Health)
  3. Industry insights on biosimilar entry and competition trends
  4. Recent legislative updates on drug pricing policies
  5. Market research on therapeutic area-specific demand dynamics

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.